Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer: 11. Alternative approaches and the future of treatment.

Literature DB >> 10081469

Prostate cancer: 11. Alternative approaches and the future of treatment.

J Trachtenberg¹, J Crook, I F Tannock.

Abstract

Entities: Disease

Mesh：

Year: 1999 PMID： 10081469 PMCID： PMC1230078

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

21 in total

1. Prostate cancer: 10. Palliative care.

Authors: N A Iscoe; E Bruera; R C Choo
Journal: CMAJ Date: 1999-02-09 Impact factor: 8.262

2. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Authors: I F Tannock; D Osoba; M R Stockler; D S Ernst; A J Neville; M J Moore; G R Armitage; J J Wilson; P M Venner; C M Coppin; K C Murphy
Journal: J Clin Oncol Date: 1996-06 Impact factor: 44.544

3. Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients.

Authors: R D Cespedes; L L Pisters; A C von Eschenbach; E J McGuire
Journal: J Urol Date: 1997-01 Impact factor: 7.450

Review 4. Treatment options for localized recurrence of prostate cancer following radiation therapy.

Authors: D A Corral; L L Pisters; A C von Eschenbach
Journal: Urol Clin North Am Date: 1996-11 Impact factor: 2.241

5. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience.

Authors: A Gelet; J Y Chapelon; R Bouvier; R Souchon; C Pangaud; A F Abdelrahim; D Cathignol; J M Dubernard
Journal: Eur Urol Date: 1996 Impact factor: 20.096

6. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer.

Authors: S M Cresswell; P J English; R R Hall; J T Roberts; M M Marsh
Journal: Br J Urol Date: 1995-09

7. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

Authors: A T Porter; A J McEwan; J E Powe; R Reid; D G McGowan; H Lukka; J R Sathyanarayana; V N Yakemchuk; G M Thomas; L E Erlich
Journal: Int J Radiat Oncol Biol Phys Date: 1993-04-02 Impact factor: 7.038

Prostate cancer: 11. Alternative approaches and the future of treatment.

1. Prostate cancer: 10. Palliative care.

2. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

3. Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients.

Review 4. Treatment options for localized recurrence of prostate cancer following radiation therapy.

5. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience.

6. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer.

7. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

8. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Review 9. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.

10. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.

1. Prostate cancer from a patient's perspective.

2. Understanding obesity.

3. The more the better?

4. Understanding obesity.

5. PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group.